Caladrius Biosciences to Participate at the 15th International Symposium on Cardiovascular Regeneration and Repair

BASKING RIDGE, N.J. , May 07, 2018 -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that Douglas Losordo, M.D., FACC, FAHA, Senior Vice President of Clinical Medical and Regulatory Affairs and Chief Medical Officer, will participate at the 15th International Symposium on Cardiovascular Regeneration and Repair being held May 10-11, 2018 in Madrid, Spain. Dr. Losordo’s presentation agenda is as follows:

First Session: From Animals to Human Health - Lessons from Clinical Science

• Date: Thursday, May 10, 2018
• Time: 2:30pm CEST

Second Session: This Year We Debate Again

• Title: Jumping to the clinics. Do we need the industry? Yes, industry partnership is essential
• Date: Thursday, May 10, 2018
• Time: 5:57pm CEST

For additional information related to the Symposium, please visit www.cardiovascularcelltherapy.com.

About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in an ongoing Phase 2 trial. CLBS14, a CD34 cell therapy intended as a treatment for coronary microvascular dysfunction and refractory angina, is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is formulated specifically for intramuscular administration for the treatment of lower extremity ischemia. A phase 2 study of CLBS12 as a treatment for critical limb ischemia being conducted in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine regulations. For more information about Caladrius please visit www.caladrius.com.

Contacts:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Executive Director, Investor Relations and Corporate Communications
Phone:  +1-908-842-0084
Email: [email protected]

LHA Investor Relations
Miriam Weber Miller
Senior Vice President
Phone: +1-212-838-3777
Email: [email protected]